middle.news
Amplia’s Narmafotinib Shows Survival Gains and Manufacturing Scale-Up
10:20am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Amplia’s Narmafotinib Shows Survival Gains and Manufacturing Scale-Up
10:20am on Tuesday 28th of April, 2026 AEST
Key Points
ACCENT trial median overall survival 11.1 months
Five complete responses and 36% objective response rate
13 kg GMP production batch completed
AMPLICITY trial recruitment halted due to chemotherapy toxicity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE